Abatacept + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Active Rheumatoid Arthritis
Conditions
Active Rheumatoid Arthritis
Trial Timeline
May 1, 2007 → May 1, 2010
NCT ID
NCT00420199About Abatacept + Placebo
Abatacept + Placebo is a phase 3 stage product being developed by Bristol Myers Squibb for Active Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00420199. Target conditions include Active Rheumatoid Arthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02108860 | Phase 3 | Completed |
| NCT02778906 | Phase 3 | Completed |
| NCT02161406 | Phase 2 | Completed |
| NCT02232880 | Phase 2 | Terminated |
| NCT01860976 | Phase 3 | Completed |
| NCT00442611 | Phase 1/2 | Completed |
| NCT00784459 | Phase 2 | Completed |
| NCT00533897 | Phase 3 | Completed |
| NCT00534313 | Phase 2 | Terminated |
| NCT00420199 | Phase 3 | Completed |
| NCT00345748 | Phase 2 | Completed |
| NCT00124449 | Phase 2 | Completed |
Competing Products
20 competing products in Active Rheumatoid Arthritis